Online citations, reference lists, and bibliographies.
← Back to Search

Novel Oral Drug Delivery Gateways For Biotechnology Products: Polypeptides And Vaccines

D. Brayden, D. O'mahony
Published 1998 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract Oral delivery of peptide, protein and vaccine biotechnology products remains the major challenge in drug delivery technology. In the main, these agents are administered to patients by injection, infusion or by subcutaneous implants. Oral delivery of intact peptide-based products is attractive because it offers improved convenience and patient compliance, and this will result in reduced overall healthcare costs. Taking into account the intestinal site of absorption and the physico-chemical properties of the agent, these labile compounds can be successfully formulated for oral delivery using intestinal-protective-, targeting- and epithelial-permeating approaches. Some of the more innovative current technologies are reviewed for these classes of biotech products.
This paper references
The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine.
D. Holt (1994)
10.1021/JS950285R
Correlation of drug absorption with molecular surface properties.
K. Palm (1996)
10.1016/0169-409X(89)90018-5
Penetration and enzymatic barriers to peptide and protein absorption
V. Lee (1989)
10.1016/S0168-3659(97)00259-9
Partially unfolded proteins efficiently penetrate cell membranes--implications for oral drug delivery.
S. Milstein (1998)
10.3109/10611869808995876
Absorption enhancement in intestinal epithelial Caco-2 monolayers by sodium caprate: assessment of molecular weight dependence and demonstration of transport routes.
T. Lindmark (1998)
10.1016/S0016-5085(97)70112-4
The oligopeptide transporter (Pept-1) in human intestine: biology and function.
S. Adibi (1997)
10.1016/0005-2736(90)90309-C
Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2.
A. Dantzig (1990)
10.1038/386410A0
Biologically erodable microspheres as potential oral drug delivery systems
E. Mathiowitz (1997)
10.1038/bjc.1997.362
Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action.
A. C. de Verdière (1997)
10.1016/0169-409X(92)90015-I
C) Means to enhance penetration
E. S. Swenson (1992)
10.1016/0168-3659(94)90071-X
Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs
X. Zhou (1994)
10.1615/CRITREVTHERDRUGCARRIERSYST.V13.I3-4.10
Current applications of polysaccharides in colon targeting.
L. Hovgaard (1996)
10.1002/JPS.2600821008
Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism.
B. Aungst (1993)
10.1016/0168-3659(90)90013-J
Nanocapsules as carriers for oral peptide delivery
C. Damgé (1990)
10.1038/9450
SAP-less chromatin triggers systemic lupus erythematosus
E. Paul (1999)
10.1016/0168-3659(95)00147-6
Intestinal drug metabolism and antitransport processes : A potential paradigm shift in oral drug delivery
L. Benet (1996)
10.1016/S0169-409X(96)00429-2
Non-antibiotic anti-diarrhoeal drugs: factors affecting oral bioavailability of berberine and loperamide in intestinal tissue
A. Baird (1997)
10.1002/JPS.2600840603
Budesonide‐β‐D‐glucuronide: A Potential Prodrug for Treatment of Ulcerative Colitis
H. Nolen (1995)
10.1016/S0168-3659(96)01536-2
Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro
H. L. Luessen (1997)
10.1038/NBT0797-653
Oral vaccination of mice against tetanus with recombinant Lactococcus lactis
K. Robinson (1997)
10.1023/A:1016030202104
Lectin-bearing Polymerized Liposomes as Potential Oral Vaccine Carriers
Hongming Chen (2004)
10.1093/OXFORDJOURNALS.QJMED.A068821
The heparin target organ--the endothelium. Studies in a rat model.
L. Hiebert (1993)
10.1172/JCI119271
Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model.
A. Fasano (1997)
10.1023/A:1012140709158
Intestinal Absorption Screening of Mixtures from Combinatorial Libraries in the Caco-2 Model
E. W. Taylor (2004)
10.1073/PNAS.94.5.2031
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
A. Sparreboom (1997)
10.3109/02652049709006810
Chitosan microcapsules as controlled release systems for insulin.
K. Aiedeh (1997)
10.1016/0306-3623(86)90198-9
Biological effect and plasma concentrations of DDAVP after intranasal and peroral administration to humans.
H. Vilhardt (1986)
10.1016/S0167-5699(97)01239-5
Immune responses to dietary antigens: oral tolerance.
S. Strobel (1998)
10.1128/IAI.66.3.1237-1243.1998
M-Cell Surface β1 Integrin Expression and Invasin-Mediated Targeting of Yersinia pseudotuberculosis to Mouse Peyer’s Patch M Cells
M. A. Clark (1998)
Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics.
T. Terada (1997)
10.1038/NM0598-607
Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato
C. Tacket (1998)
10.1016/S0928-0987(97)10007-0
Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia.
S. McClean (1998)
10.1021/JS9601400
Transcellular delivery of an insulin-transferrin conjugate in enterocyte-like Caco-2 cells.
D. Shah (1996)
10.1023/A:1016033702220
The Use of Surfactants to Enhance the Permeability of Peptides Through Caco-2 Cells by Inhibition of an Apically Polarized Efflux System
M. Nerurkar (2004)
Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen.
S. Challacombe (1992)
10.1016/S0074-7696(08)61346-7
M cells in Peyer's patches of the intestine.
A. Gebert (1996)
10.1016/0168-3659(95)00055-D
Penetration enhancement effect of Pz-peptide, a paracellularly transported peptide, in rabbit intestinal segments and Caco-2 cell monolayers
W. Yen (1995)
10.3109/10611869608995624
Oral protein drug delivery.
W. Wang (1996)
10.1111/J.1365-2125.1995.TB04459.X
Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function.
D. Proppe (1995)
10.1023/A:1018962415287
Oral Absorption of Peptides: The Effect of Absorption Site and Enzyme Inhibition on the Systemic Availability of Metkephamid
P. Langguth (2004)
10.1677/JOE.0.1310267
Oral insulin in diabetic dogs.
M. Saffran (1991)
10.1016/0378-5173(95)04204-0
Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo
H. Lennernäs (1996)
10.1126/SCIENCE.277.5328.949
Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria.
S. Kernéis (1997)
10.1021/JS960182O
Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers.
T. Aspden (1997)
10.1002/JPS.2600821002
Aqueous acidic degradation of the carbacephalosporin loracarbef.
M. J. Skibic (1993)
10.1016/0168-3659(90)90133-E
Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches
J. Eldridge (1990)



This paper is referenced by
10.2165/00137696-200503030-00003
Polymer colon drug delivery systems and their application to peptides, proteins, and nucleic acids
S. Bourgeois (2005)
10.1016/S1359-6446(00)01600-7
Innovations in oral gene delivery: challenges and potentials.
D. T. Page (2001)
10.1016/j.ijpharm.2019.05.037
In-vitro evaluation of solid lipid nanoparticles: Ability to encapsulate, release and ensure effective protection of peptides in the gastrointestinal tract.
Camille Dumont (2019)
10.1080/02652040802485725
In vitro evaluation of chondroitin sulphate-chitosan microspheres as carrier for the delivery of proteins
K. Maculotti (2009)
10.1023/B:PHAM.0000022418.80506.9a
In Vivo Phage Display to Identify M Cell-Targeting Ligands
Lisa M. Higgins (2004)
Avances en tecnología farmacéutica
A. Hurlé (2004)
10.1517/14712598.2.1.67
Targeting approaches to oral drug delivery
I. Lambkin (2002)
10.1016/J.MSEC.2011.10.025
Interaction between bradykinin potentiating nonapeptide (BPP9a) and β-cyclodextrin: A structural and thermodynamic study
I. Lula (2012)
10.2174/138161209789271834
Angiotensin converting enzyme (ACE) inhibitory peptides: production and implementation of functional food.
F. De Leo (2009)
10.1016/S0928-0987(01)00175-0
Oral vaccination in man using antigens in particles: current status.
D. Brayden (2001)
10.1016/j.vetimm.2008.07.002
Chitosan microspheres as candidate plasmid vaccine carrier for oral immunisation of Japanese flounder (Paralichthys olivaceus).
Jiyuan Tian (2008)
10.1023/A:1016188312399
Alginate/Poly-L-Lysine Microparticles for the Intestinal Delivery of Antisense Oligonucleotides
María González Ferreiro (2004)
10.1002/9783527812172.ch12
Formulation of Therapeutic Proteins: Strategies for Developing Oral Protein Formulations
S. Patil (2019)
10.1002/PSC.467
Lipid and carbohydrate based adjuvant/carriers in immunology
R. McGeary (2003)
10.1016/j.ijpharm.2009.10.027
M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes.
A. Shukla (2010)
Release and activity of ACE inhibitory peptides from pea and whey protein
V. Vermeirssen (2003)
10.1021/bm401580k
Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration.
A. Agrawal (2014)
Towards the development of a multicomponent, nanoscale oral vaccine delivery system targeting infectious bursal disease (IBD)
Wendy Marie Pettit (2013)
EFFECT OF ALOE VERA JUICE ON THE TOXICITY INDUCED BY ISONIAZID AND RIFAMPICIN DRUGS ON COMPLETE BLOOD COUNT IN MALE WISTAR RATS
P. P. Bhise (2016)
10.1016/j.ijpharm.2018.02.038
Lipid-based nanosuspensions for oral delivery of peptides, a critical review.
Camille Dumont (2018)
10.2165/00063030-200620050-00004
A Supramolecular Complex between Proteinases and β-Cyclodextrin that Preserves Enzymatic Activity
Ângelo M. L. Denadai (2012)
10.1079/BJN20041189
Bioavailability of angiotensin I converting enzyme inhibitory peptides.
V. Vermeirssen (2004)
10.1201/B19038
Handbook of Encapsulation and Controlled Release
M. Mishra (2015)
10.1016/j.jconrel.2015.05.258
Oral films as breakthrough tools for oral delivery of proteins/peptides.
P. Castro (2015)
10.1517/17425247.2016.1142526
Recent advances in oral delivery of peptide hormones
Pegah Varamini (2016)
10.1055/s-0029-1185341
Intestinal drug transport enhancement by Aloe vera.
W. Chen (2009)
10.1016/S0264-410X(03)00432-8
Antigen-specific IgA and IgG responses in calves inoculated intranasally with ovalbumin encapsulated in poly(DL-lactide-co-glycolide) microspheres.
O. Kavanagh (2003)
10.1016/S0169-409X(01)00149-1
Exploiting M cells for drug and vaccine delivery.
M. A. Clark (2001)
10.1016/S0169-409X(00)00070-3
Lectin-mediated mucosal delivery of drugs and microparticles.
M. A. Clark (2000)
10.2165/00137696-200604020-00002
Oral delivery of hematopoietic factors
K. Takada (2006)
10.3390/molecules13081599
Composition and Applications of Aloe vera Leaf Gel
J. Hamman (2008)
10.1016/j.biotechadv.2014.07.006
A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules.
Bibi F Choonara (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar